Skip to search formSkip to main contentSkip to account menu

anacetrapib

A cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties. Anacetrapib reduces the transfer of cholesteryl ester from… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Anticholesteremic AgentsOxazolidinones
MK 0859

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk.
2017
2017
CETP Inhibitors - A New Inning?
Former baseball manager Tony La Russa once said, “Even when you have three strikes, you’re still not out. There is always… 
2013
2013
Effects of Rifampin, a Potent Inducer of Drug‐Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib
Anacetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor in development for treatment of dyslipidemia. This… 
2012
2012
Anacetrapib, a cholesteryl ester transfer protein inhibitor
Introduction: Inhibition of cholesteryl ester transfer protein (CETP) has the ability to increase high-density lipoprotein (HDL… 
2012
2012
SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
2011
2011
Learning lessons from Pfizer's $800 million failure
2011
2011
Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as… 
Review
2011
Review
2011
Emerging therapeutic strategies to enhance HDL function
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and… 
Review
2009
Review
2009
The end of the road for CETP inhibitors after torcetrapib?
Purpose of review Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease… 
Review
2009
Review
2009
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Anacetrapib, under development by Merck & Co Inc, is an inhibitor of the cholesterol ester transfer protein (CETP) for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)